Literature DB >> 10377424

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.

M V Karpuj1, H Garren, H Slunt, D L Price, J Gusella, M W Becher, L Steinman.   

Abstract

The protein huntingtin (htt), aggregated in neuronal nuclear inclusions, is pathognomonic of Huntington's disease (HD). Constructs, translated in vitro from the N terminus of htt, containing either polyQ23 from a normal individual, or polyQ41 or polyQ67 from an HD patient, were all soluble. Transglutaminase (TGase) crosslinked these proteins, and the aggregations did not have the staining properties of amyloid. More TGase-catalyzed aggregates formed when the polyglutamine domain of htt exceeded the pathologic threshold of polyQ36. Furthermore, shorter htt constructs, containing 135 aa or fewer, formed more aggregates than did larger htt constructs. TGase activity in the HD brain was increased compared with the control, with notable increases in cell nuclei. The increased TGase activity was brain specific. In lymphoblastoid cells from HD patients, TGase activity was decreased. TGase-mediated crosslinking of htt may be involved in the formation of the nonamyloidogenic nuclear inclusions found in the HD brain. The staining properties of nuclear inclusions in the HD brain revealed that they were not amyloid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10377424      PMCID: PMC22095          DOI: 10.1073/pnas.96.13.7388

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.

Authors:  Y P Goldberg; D W Nicholson; D M Rasper; M A Kalchman; H B Koide; R K Graham; M Bromm; P Kazemi-Esfarjani; N A Thornberry; J P Vaillancourt; M R Hayden
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

2.  Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?

Authors:  A J Cooper; K F Sheu; J R Burke; O Onodera; W J Strittmatter; A D Roses; J P Blass
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

3.  Transglutaminase activity is increased in Alzheimer's disease brain.

Authors:  G V Johnson; T M Cox; J P Lockhart; M D Zinnerman; M L Miller; R E Powers
Journal:  Brain Res       Date:  1997-03-21       Impact factor: 3.252

4.  Neurodegenerative diseases and transglutaminase.

Authors:  L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 5.  The neuropathology of CAG repeat diseases: review and update of genetic and molecular features.

Authors:  Y Robitaille; I Lopes-Cendes; M Becher; G Rouleau; A W Clark
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

6.  Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism.

Authors:  H Green
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

Review 7.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

Authors:  J D Harper; P T Lansbury
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

8.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

9.  Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease.

Authors:  L Cariello; T de Cristofaro; L Zanetti; T Cuomo; L Di Maio; G Campanella; S Rinaldi; P Zanetti; R Di Lauro; S Varrone
Journal:  Hum Genet       Date:  1996-12       Impact factor: 4.132

10.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.

Authors:  M F Perutz; T Johnson; M Suzuki; J T Finch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

View more
  51 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Increased levels of gamma-glutamylamines in Huntington disease CSF.

Authors:  Thomas M Jeitner; Wayne R Matson; John E Folk; John P Blass; Arthur J L Cooper
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

4.  Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Authors:  Ying Dai; Nichole L Dudek; Qian Li; Stephen C Fowler; Nancy A Muma
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

5.  Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Authors:  Soo-Youl Kim; Lyuben Marekov; Parvesh Bubber; Susan E Browne; Irina Stavrovskaya; Jongmin Lee; Peter M Steinert; John P Blass; M Flint Beal; Gary E Gibson; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

Review 6.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 7.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

Review 8.  Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Janghoo Lim
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

9.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

10.  Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.

Authors:  Nichole L Dudek; Ying Dai; Nancy A Muma
Journal:  Brain Pathol       Date:  2009-03-10       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.